生命银行
基因组
生物
全基因组关联研究
遗传学
计算生物学
数量性状位点
表型
单核苷酸多态性
遗传关联
基因组学
疾病
拷贝数变化
人类基因组
增强子
基因
精密医学
表达数量性状基因座
遗传力缺失问题
人类遗传变异
遗传变异
人类遗传学
DNA微阵列
生物信息学
1000基因组计划
微阵列
一致性
结构变异
突变
作者
Xueqing Zoe Zou,Fengyuan Hu,Haiyi Lou,Oliver S. Burren,Xiaoyin Li,Karyn Megy,Eleanor Wheeler,Qiang Wu,Satbhai Santosh,Marcin Karpiński,Douglas Loesch,Zammy Fairhurst-Hunter,Sri V. V. Deevi,Erin Oerton,Sean Wen,Xiao Jiang,Cecilia Salvoro,Jonathan Mitchell,Abhishek Nag,Ben Hollis
出处
期刊:Nature
[Nature Portfolio]
日期:2026-02-04
标识
DOI:10.1038/s41586-025-10087-x
摘要
Copy number variants (CNVs) are key drivers of human diversity and disease risk1. Here we evaluate the role of CNVs across a broad range of human phenotypes and diseases by analysing CNVs from 470,727 UK Biobank whole-genome sequences and conducting a variant- and gene-level phenome-wide association study (PheWAS) with 2,941 plasma protein abundance measurements, 13,336 binary clinical phenotypes and 1,911 quantitative traits. Proteomic analyses validated functional associations of CNVs with nearby genes (cis-protein quantitative trait loci; cis-pQTLs)-with deletions and duplications typically associated with reduced and increased protein levels, respectively-and uncovered previously unknown protein-protein interactions (trans-pQTLs). Our PheWAS recapitulated known associations and uncovered associations in both coding and non-coding regions. Notably, we identified a rare deletion in ZNF451 associated with increased leukocyte telomere length and a non-coding deletion of a SLC2A9 enhancer associated with reduced gout risk. In addition, by combining CNVs with protein-coding single nucleotide variants and indels, we enhanced the power of our study to detect gene-disease associations. Finally, we leveraged this multiomics dataset to identify several pQTLs that constitute candidate biomarkers, including TMPRSS5 for Charcot-Marie-Tooth disease type 1A. This multiancestry whole-genome-sequence CNV PheWAS offers insights into the roles of CNVs in human health outcomes and could serve as a valuable resource for therapeutic development.
科研通智能强力驱动
Strongly Powered by AbleSci AI